AnPac Files for Coronavirus Detection Patent
AnPac Bio-Medical Science Co. Ltd. (Nasdaq: ANPC) announced on Thursday that it has filed a preliminary patent application in the United States related to the detection of the coronavirus.
The biotechnology company, which completed its initial public offering on the Nasdaq Global in late January, said in a statement today that the submission may lead to formal patent applications in China and other countries. AnPac filed the provisional patent application on Feb. 10.
In addition, AnPac said it has partnered with a hospital in China to launch research into the use of AnPac's cancer differentiation analysis (CDA) technology to detect the risk of COVID-19.
With offices in China and the United States, AnPac was the first in the world to develop a cancer detection and screening test based on the biophysical properties of blood. While its technology primarily focuses on the detection of cancer, it may also detect non-cancerous diseases.
"Exploring the CDA technology's ability to detect the risk of major non-cancerous diseases and broadening its product offerings for other life threatening diseases has been part of AnPac Bio's business strategies for years," AnPac's chairman and chief executive, Dr. Chris Yu, said in the statement today.
As of September, AnPac owned 121 patents, of which 16 were in the United States. More than 100 patents of the company are pending globally.
AnPac became publicly traded in New York on Jan. 30, raising $16 million for 1.3 million of its American depositary shares. On Thursday, the stock in the company closed at $9.70 per share, down 3% on the day.
Luckin Continues to Lost amid Scandal; Market Begins to Take a Breath,
Hang Seng Index Loses Ground After COVID-19 Cases Exceed 1 Million
Chinese Coffee Company Runs Out of Luckin; Stock Tanks 85%
Chinese Oil Players Gain as Crude-Oil Jumps, Luckin Plunges 76%
AMC Stock Down 4% on Debt Restructuring Talks
Hong Kong Oil and Gas Stocks Gain on Trump's Optimism for Potential Saudia Arabia-Russia Deal